Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL28605909 | 0.98 | AGXT (0.52) | AGXTCA1CA2CA9IDO1 | |
| SCHEMBL649272 | 0.90 | IDO1 (0.44) | AGXTIDO1TAAR1 | |
| SCHEMBL29599465 | 0.86 | AGXT (0.54) | AGXTCA1CA2CA9IDO1 | |
| SCHEMBL12243070 | 0.84 | AGXT (0.40) | AGXTCA1CA2CA9KCNH2 | |
| SCHEMBL1337524 | 0.83 | IDO1 (0.41) | AGXTIDO1MAOB | |
| SCHEMBL23180521 | 0.82 | AGXT (0.56) | AGXTCA1CA2CA9IDO1 | |
| SCHEMBL14443338 | 0.82 | AGXT (0.50) | AGXTCA1CA2CA9IDO1 | |
| SCHEMBL22156173 | 0.82 | AGXT (0.50) | AGXTCA1CA2CA9IDO1 | |
| SCHEMBL21505013 | 0.81 | ADRB2 (0.50) | AGXTCA1CA2CA9IDO1 | |
| SCHEMBL12134040 | 0.81 | ACACB (0.39) | AGXTIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183164-A1 | Synthesis of Vinyl Cyclobutyl Intermediates | AMGEN INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-10940139-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200121660-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, INC. | 2020-04-23 | — | — | US | disclosed |
| US-10221191-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC | 2019-03-05 | — | — | US | disclosed |
| US-20180051031-A1 | SECO-CYCLOPROPAPYRROLOINDOLE COMPOUNDS, ANTIBODY-DRUG CONJUGATES THEREOF, AND METHODS OF MAKING AND USE | THE SCRIPPS RESEARCH INSTITUTE | 2018-02-22 | — | — | US | disclosed |
| US-9802952-B2 | Method and apparatus for the synthesis of dihydroartemisinin and artemisinin derivatives | Max-Plank-Gesellschaft zur Förderung der Wissenschaften e.v. (DE) | 2017-10-31 | — | — | US | disclosed |
| US-9802952-B2 | Method and apparatus for the synthesis of dihydroartemisinin and artemisinin derivatives | Max-Plank-Gesellschaft zur Förderung der Wissenschaften e.v. (DE) | 2017-10-31 | — | — | US | disclosed |
| US-9796716-B2 | Selective inhibitors of Tec and Src protein kinase families | PHARMASCIENCE, INC. (CA) | 2017-10-24 | — | — | US | disclosed |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
| US-20110218177-A1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2011-09-08 | — | — | US | disclosed |
| US-7250246-B2 | Positive resist composition and pattern formation method using the same | FUJIFILM CORPORATION (JP) | 2007-07-31 | — | — | US | disclosed |
| US-7250246-B2 | Positive resist composition and pattern formation method using the same | FUJIFILM CORPORATION (JP) | 2007-07-31 | — | — | US | disclosed |
| US-7226950-B2 | Sodium channel modulators | THERAVANCE, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| EP-0268878-B1 | Salicylic acid copolymers and their metal salts, production process thereof, color-developing agents comprising metal salts of the copolymers and color-developing sheets employing the agents | MITSUI TOATSU CHEMICALS (JP) | 1996-01-31 | — | — | EP | disclosed |
| US-5447901-A | Color-developing sheet: base material coated with composition of /a/ multivalent metal-modified salicylic acid resin formed from salicylic acid, a benzyl compound and optional styrene and /b/ analogous resin free of salicylic acid | MITSUI TOATSU CHEMICAL, INC. (JP) | 1995-09-05 | — | — | US | disclosed |
| US-5376615-A | Pressure sensitive elements containing a salicylic acid resin and a phenolic resin | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1994-12-27 | — | — | US | disclosed |
| US-5023366-A | Reacted with a benzyl halide, alcohol or ether; for pressure sensitive elements | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1991-06-11 | — | — | US | disclosed |
| EP-0268878-A2 | Salicylic acid copolymers and their metal salts, production process thereof, color-developing agents comprising metal salts of the copolymers and color-developing sheets employing the agents | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1988-06-01 | — | — | EP | disclosed |
| US-4113782-A | CATALYTIC OXIDATION | AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221191-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | AGXT 2540/4885CA1 4238/4885CA2 4222/4885 |
| US-20110218177-A1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | CETP, SLCO2B1, OXA1L | AGXT 1519/4885CA1 3388/4885CA2 3271/4885 |
| US-20230183164-A1 | Synthesis of Vinyl Cyclobutyl Intermediates | MCL1, BCL2A1, BAK1 | AGXT 3957/4885CA1 2891/4885CA2 2956/4885 |
| US-20200121660-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | HRAS, KRAS, NRAS | AGXT 3646/4885CA1 4870/4885CA2 4606/4885 |
| US-10940139-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | AGXT 3646/4885CA1 4870/4885CA2 4606/4885 |
| US-20180051031-A1 | SECO-CYCLOPROPAPYRROLOINDOLE COMPOUNDS, ANTIBODY-DRUG CONJUGATES THEREOF, AND METHODS OF MAKING AND USE | CD22, GDI2, GDI1 | AGXT 4156/4885CA1 1345/4885CA2 3406/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | AGXT 2540/4885CA1 4238/4885CA2 4222/4885 |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | AGXT 893/4885CA1 4843/4885CA2 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.